PMID- 11586282
OWN - NLM
STAT- MEDLINE
DCOM- 20011204
LR  - 20190723
IS  - 0091-6749 (Print)
IS  - 0091-6749 (Linking)
VI  - 108
IP  - 4 Suppl
DP  - 2001 Oct
TI  - Intravenous immunoglobulin consensus statement.
PG  - S139-46
AB  - Intravenous immunoglobulin (IVIG) preparations are a mainstay for a number of 
      disorders that include primary immuno-deficiency, acute inflammatory conditions, 
      hematological disorders, infections, and neuroimmunological disorders. The range 
      of therapeutic activity is attributed to IVIG's myriad action mechanisms. IVIG 
      can interact and bind onto complement factors, which can prevent 
      complement-mediated tissue damage, modulate T-lymphocytes, alter cytokine 
      profiles, and modulate the immune system. These interactions can act alone or in 
      combination to maintain immune balance while preserving homeostasis. A consensus 
      panel was convened in 2000 to evaluate and define new advances in IVIG therapies.
FAU - Sacher, R A
AU  - Sacher RA
AD  - University of Cincinnati Medical Center, OH 45267-0055, USA.
CN  - IVIG Advisory Panel
LA  - eng
PT  - Consensus Development Conference
PT  - Journal Article
PT  - Review
PL  - United States
TA  - J Allergy Clin Immunol
JT  - The Journal of allergy and clinical immunology
JID - 1275002
RN  - 0 (Immunoglobulins, Intravenous)
SB  - IM
MH  - Female
MH  - Humans
MH  - Immunoglobulins, Intravenous/*therapeutic use
MH  - Pregnancy
RF  - 76
EDAT- 2001/10/05 10:00
MHDA- 2002/01/05 10:01
CRDT- 2001/10/05 10:00
PHST- 2001/10/05 10:00 [pubmed]
PHST- 2002/01/05 10:01 [medline]
PHST- 2001/10/05 10:00 [entrez]
AID - a118640 [pii]
AID - 10.1067/mai.2001.118640 [doi]
PST - ppublish
SO  - J Allergy Clin Immunol. 2001 Oct;108(4 Suppl):S139-46. doi: 
      10.1067/mai.2001.118640.